September 10, 2025MedicineOpen Access

Mendelian randomization reveals causal circulatory microRNAs in prostate cancer pathogenesis and prognosis

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Mendelian randomization reveals five protective microRNAs in prostate cancer, suggesting new biomarkers and therapeutic targets.

Five microRNAs showed an inverse association with prostate cancer risk, indicating potential protective factors.
Using Mendelian randomization, the study validated two microRNAs with a significant odds ratio for prostate cancer.
Survival analysis highlighted nine genes linked to microRNAs that are enriched in critical pathways relevant to cancer.
The identified microRNAs could serve as noninvasive biomarkers for prostate cancer diagnosis and treatment options.

Cong et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark